###begin article-title 0
Association of Vascular Endothelial Growth Factor Gene Polymorphisms with Susceptibility and Clinicopathologic Characteristics of Colorectal Cancer
###end article-title 0
###begin p 1
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 930 931 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 988 992 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1126 1130 1126 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1221 1225 1221 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 773 781 <span type="species:ncbi:9606">patients</span>
Since vascular endothelial growth factor (VEGF) is known to be a potent pro-angiogenic factor, we evaluated the potential association of two VEGF gene polymorphisms (-634G>C and 936C>T) with the susceptibility and the clinicopathologic characteristics of colorectal cancer (CRC). The VEGF genotypes were determined using fresh colorectal tissue from 465 patients who had undergone a surgical resection and peripheral blood lymphocytes from 413 healthy controls by PCR/DHPLC assay. For the -634G>C polymorphism, the -634 GC or CC genotype was associated with a decreased risk of CRC (odds ratio [OR], 0.62; p=0.001) as a dominant model of C allele, whereas the 936 TT genotype correlated with advanced stage/ metastasis, a high serum level of CA19-9, and an higher grade in patients with CRC. In the haplotype analyses, haplotype -634C/936C and -634G/936T were associated with a decreased susceptibility of CRC (OR, 0.53 and 0.56; p<0.001, respectively). These observations imply that the VEGF gene polymorphisms may be associated with the susceptibility or clinicopathologic features of CRC. However, further studies of other VEGF sequence variants and their biological functions are needed to understand the role of the VEGF gene polymorphisms in the development and progression of CRC.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Colorectal cancer (CRC) is the second leading cause of cancer- related deaths in the U.S.A. and Europe (1). During the last few years, many attempts have been made to define the biological profile of CRC in order to improve early diagnosis and the prognostic stratification, and eventually find a cure (2, 3). Although many biological factors have been implicated in the development of CRC, a clinical relevance has not yet been reached for most of them.
###end p 3
###begin p 4
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
Angiogenesis, the formation of a new blood vessel from endothelial precursors, is a prerequisite for the development, growth, and progression of solid malignancies (4). The vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays a critical role in angiogenesis. VEGF specifically binds to VEGF receptor tyrosine kinase on endothelial cells to initiate intracellular signal transduction pathways that mediate angiogenesis and vascular permeability. In addition to stimulating angiogenesis, VEGF may also have autocrine functions, acting as a survival factor for tumor cells by protecting them from various forms of stress and apoptosis (5-8).
###end p 4
###begin p 5
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 724 728 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 873 877 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
The VEGF gene is located on chromosome 6p21.3 and consists of eight exons that exhibit alternative splicing to form a family of proteins (9, 10). Several polymorphisms have been associated with variations in VEGF protein production and reported to be involved in the development of several tumors (11, 12) and autoimmune diseases (13, 14). Given these results, it is also possible that a functional genetic variation in the VEGF gene may contribute to the development and progression of CRC. However, there have been no studies in the literature that have investigated the single nucleotide polymorphisms (SNPs) of the VEGF gene and their relationship to the susceptibility of CRC. Accordingly, the present study examined 2 VEGF gene polymorphisms (-634G>C and 936C>T)previously reported to be related with VEGF production, and evaluated the potential association of three VEGF gene polymorphisms with the susceptibility and clinicopathologic characteristics of CRC in the Korean population.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Study populations
###end title 7
###begin p 8
###xml 80 88 <span type="species:ncbi:9606">patients</span>
All the tissues investigated in this study were obtained from 465 native Korean patients with CRC who had undergone a surgical resection between January 2003 and August 2006 at Kyungpook National University Hospital (Daegu, Korea). Based on a health-screening questionnaire, 413 unrelated, healthy Korean individuals without known medical problems were also enrolled as the control group. The study was approved by the Institutional Research Board of Kyungpook National University Hospital, and all individuals gave written informed consent for study participation.
###end p 8
###begin p 9
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
The diagnosis and staging of the colorectal adenocarcinoma were assessed according to the WHO classification (15) and TNM classification set out by the American Joint Committee on Cancer (AJCC-UICC) (16).
###end p 9
###begin title 10
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Genotyping of VEGF gene polymorphisms
###end title 10
###begin p 11
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1078 1079 1074 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1084 1085 1080 1081 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1087 1088 1083 1084 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1090 1091 1086 1087 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 175 182 <span type="species:ncbi:9606">patient</span>
The extraction of genomic DNA from the peripheral blood lymphocytes of the control group was performed using proteinase- K digestion and phenol/chloroform extraction. For the patient group, the genomic DNA was extracted from fresh colorectal tumor tissue at the time of surgery using a Wizard genomic DNA purification kit (Promega, Madison, WI, U.S.A.). The VEGF -634G>C and 936C>T genotypes were determined using a polymerase chain reaction/denaturing high-performance liquid chromatography (PCR/DHPLC) assay as described in the previous studies (17, 18). PCR primers were designed based on a Genbank reference sequence (accession no. NT_007592). The PCR primers used for the -634G>C and 936C>T polymorphisms were 5'-CGACGGCTTGGGGAGATTGC- 3'(forward) and 5'-GGGCGGTGTCTGTCTGTCTG- 3'(reverse); and 5'-AGGGTTTCGGGAACCAGATC- 3'(forward) and 5'-CTCGGTGATTTAGCAGCAAG- 3'(reverse), respectively. The PCR reactions were performed in a 50-microL reaction volume containing 50 ng genomic DNA, 50 pM/L each primer, 10 mM/L dNTP, 5xQ- solution, 10xPCR buffer (Tris-HCl , KCl, 15 mM/L MgCl2, [NH2] 2SO4; pH8.7) and 2.5 units of HotStarTaq polymerase (QIAGEN, Hilden, Germany). The PCR cycle conditions consisted of an initial denaturation step at 94℃ for 15 min, followed by 40 cycles of 45 sec at 94℃, 45 sec at 57℃, 45 sec at 72℃, and a final elongation at 72℃ for 10 min. The PCR products were denatured at 94℃ for 10 min, and hybridized for 45 min, and screened for a heterozygous polymorphism based on a DHPLC analysis using a gradient solution of 0.1 M TEAA (pH 7.0), 0.1 M TEAA, 25% acetonitrile, a washing solution with 8% acetonitrile (syringe washing solution), and 75% acetonitrile (DNASep(R) Cartridge UltraClean and Storage Solution, Transgenomic, Omaha, NE, U.S.A.), Column: alkylated nonporous poly (styrene-divinylbenzene) DNASep(R) Cartridge (Transgenomic, Omaha, NE, U.S.A.), flow rate: 0.9 mL/min, oven temperature: 64℃, and UV: 260 nm.
###end p 11
###begin p 12
###xml 426 432 426 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
The remaining samples showing a single peak on the DHPLC were mixed with the PCR products of a known homozygous genotype (homozygous A), and hybridized to run the DHPLC again, as described above. Another type of homozygous genotype (homozygous B) was confirmed when a double peak appeared on the DHPLC. Several samples with three different patterns on the DHPLC were directly sequenced to reconfirm the accuracy of the DHPLC (Fig. 1).
###end p 12
###begin title 13
Statistical analyses
###end title 13
###begin p 14
###xml 79 80 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 390 391 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 620 624 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 631 633 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 640 641 636 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 368 375 <span type="species:ncbi:9606">patient</span>
The Hardy-Weinberg equilibrium for each polymorphism was analyzed using the chi2 test, which was also used to examine the statistical significance of the differences in the allele frequency and genotype distribution between the groups. The odds ratios (ORs) and 95% confidence intervals (CIs) were obtained using an unconditional logistic regression analysis. For the patient group, the chi2-test or ANOVA was used to evaluate the relation between each polymorphism and the tumor characteristics. The software PHASE (version 2.1), which uses a Bayesian statistical method, was used to reconstruct the haplotypes for the VEGF gene (19). The p value was generated using a 2-sided test. The analyses were conducted using SPSS version 12.0 (SPSS, Chicago, IL, U.S.A.) and SAS Genetic software (SAS Institute, Cary, NC, U.S.A.).
###end p 14
###begin title 15
RESULTS
###end title 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 16
###begin p 17
###xml 74 81 74 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 219 226 <span type="species:ncbi:9606">patient</span>
The clinical and pathologic characteristics of patients are summarized in Table 1. The median age of the patients was 64 (range, 21-89) yr, and 248 patients (51.8%) were male. There was no difference in age between the patient and control groups, while there was a male predominance in the control group. The pathologic stages after the surgical resection were as follows: stage I (n=80, 17.2%), stage II (n=157, 33.8 %), stage III (n=157, 33.8%), and stage IV (n=71, 15.3%).
###end p 17
###begin title 18
Genotype frequencies
###end title 18
###begin p 19
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 141 148 141 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 800 807 <span type="species:ncbi:9606">patient</span>
The VEGF genotypes were successfully identified in all 878 enrolled subjects, and the frequencies of the genotypes and alleles are listed in Table 2. The genotype distributions of the two polymorphisms among the patients and controls followed the Hardy-Weinberg equilibrium, and the frequencies of the -634C and 936T alleles among the healthy Koreans were 0.473 and 0.209, respectively. The incidence of each genotype with the -634G>C polymorphism differed between the two groups (p=0.001), where the combined GC and CC genotype was significantly associated with a decreased risk of CRC (OR, 0.62; 95% CI, 0.47-0.83; p=0.001) compared with the GG genotype as the dominant model for the C allele. For the 936C>T polymorphism, there was no difference in the genotype or allele distribution between the patient and control groups (p=0.64 and 0.71, respectively).
###end p 19
###begin title 20
Association of genotypes with clinicopathologic features
###end title 20
###begin p 21
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 399 406 399 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 8 15 <span type="species:ncbi:9606">patient</span>
For the patient group, the TT genotype of 936C>T polymorphism was significantly associated with advanced stage (OR, 3.83; 95% CI, 1.22-12.03; p=0.02), distant metastasis (OR, 8.38; 95% CI, 3.00-23.51; p<0.001), high serum level of CA19-9 (OR, 2.96; 95% CI, 1.04-8.40; p=0.04), and higher grade (p=0.002). However, no association of -634G>C polymorphism with clinicopathologic features was observed (Table 3, 4).
###end p 21
###begin title 22
Haplotype analyses
###end title 22
###begin p 23
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 106 113 106 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">Table 5</xref>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 307 314 <span type="species:ncbi:9606">patient</span>
The VEGF -634G>C and 936C>T polymorphisms exhibited an intermediate linkage disequilibrium (D'=0.50), and Table 5 shows the frequencies and ORs of the 4 reconstructed haplotypes for the two polymorphisms of the VEGF gene, as predicted by a Bayesian algorithm. Haplotype GC was the most frequent type in the patient group (41.5%), whereas haplotype CC was most frequent in the control group (43.1%). When compared with wild type (GC), the haplotype CC (OR, 0.53; 95% CI, 0.43-0.66; p<0.001) and GT (OR, 0.56; 95% CI, 0.42-0.74; p<0.001) were significantly associated with a decreased susceptibility of CRC. However, no significant associations were observed between any of the haplotypes and the clinical features of CRC (data not shown).
###end p 23
###begin title 24
DISCUSSION
###end title 24
###begin p 25
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1116 1120 1116 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1181 1185 1181 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1309 1313 1309 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1343 1345 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1347 1349 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
###xml 1011 1018 <span type="species:ncbi:9606">patient</span>
The present study investigated the potential impact of 2 VEGF gene polymorphisms on the susceptibility and clinicopathologic features of colorectal adenocarcinoma in quite a large population of Korean patients. As a result, the frequencies of -634C and 936T alleles were 0.473 and 0.209, respectively, which differ from those of Japanese (0.353 and 0.150, respectively) as well as those of Caucasians (0.335 and 0.150, respectively) (20, 21). Moreover, it was observed that the combined GC and CC genotypes of the -634G>C polymorphism, and haplotype -634C/936C and -634G/936T were associated with a decreased susceptibility, while 936 TT genotype with an adverse clinicopathologic feature of CRC. Given the homogenous ethnic background of the Korean patients, any potential confounding effect due to ethnicity is likely to be small in the present study. However, these results might be caused by somatic alteration in the process of colorectal carcinogenesis because tumor tissue was used for DNA source of the patient group in the present study, although data on the difference between germline and somatic SNPs of VEGF gene have not been reported. Furthermore, the effect of the VEGF gene polymorphisms on the susceptibility of CRC may be due to linkage disequilibrium with other functional variants in the VEGF gene or other cytokine gene (22, 23).
###end p 25
###begin p 26
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Since VEGF or its family plays a critical role in tumor-related angiogenesis, several functional polymorphisms in the VEGF gene have already been reported to be associated with a VEGF gene expression or an increased risk of solid tumors (11, 12, 23, 24), making them potential predictive markers for clinical outcomes (22-24). For example, the -634C and 936T alleles as a dominant model or CGT haplotype (-1498T >C, -634G>C, and 936C>T) among the VEGF gene polymorphisms have been associated with a significantly decreased risk of small cell lung cancer (SCLC), while the TCC haplotype conferred a significantly increased risk of SCLC in a previous study by the present authors (25). Plus, a strong association between the -634 CC or 936 TT genotypes and a larger tumor size was observed, while the -634 CC genotypes was strongly correlated with poor differentiation and advanced stage of disease in gastric cancer (24).
###end p 26
###begin p 27
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1195 1197 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
One possible explanation for these results is that the DNA sequence variations in the VEGF gene may alter VEGF production and/or activity, thereby causing inter-individual differences in the development and progression of tumors. A few studies have already reported that VEGF gene polymorphisms are associated with VEGF production, yet the results are inconsistent. Awata et al. (26) reported an association between the -634 CC genotype and a higher serum VEGF concentration in the normal Japanese population. Koukourakis et al. (27) also reported that genetic polymorphisms including the -634 region were correlated with VEGF protein expression in cancer cells and angiogenesis in tumor tissue. Renner et al. (28) demonstrated that VEGF plasma levels were significantly lower in carriers of the 936T allele, whereas Krippl et al. (23) reported that the 936T allele was associated with a lower VEGF plasma level and decreased risk of breast cancer (OR, 0.51; 95% CI, 0.38-0.70). Meanwhile, Watson et al. (10) documented that the GG genotype for the -634G>C polymorphism was significantly correlated with higher VEGF production from stimulated peripheral blood mononuclear cells. Stevens et al. (29) also reported that haplotype -460C/+405G had a higher promoter activity than haplotype -460T/+405C.
###end p 27
###begin p 28
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
In summary, the -634G>C and 936C>T polymorphisms in the VEGF gene was found to be associated with susceptibility or adverse clinicopathologic features of CRC in the current study. However, further studies of other VEGF sequence variants and their biological functions are needed to understand the role of the VEGF polymorphisms and haplotypes in the development and progression of CRC. Moreover, since genetic polymorphisms often vary between ethnic groups, more studies are also warranted to clarify the association between the VEGF polymorphisms and CRC in diverse ethnic populations.
###end p 28
###begin article-title 29
Global cancer statistics, 2002
###end article-title 29
###begin article-title 30
What's new with tumor markers for colorectal cancer?
###end article-title 30
###begin article-title 31
Tumor markers and colorectal cancer: utility in management
###end article-title 31
###begin article-title 32
Vascular-specific growth factors and blood vessel formation
###end article-title 32
###begin article-title 33
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
###end article-title 33
###begin article-title 34
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells
###end article-title 34
###begin article-title 35
Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for antiangiogenic therapy
###end article-title 35
###begin article-title 36
Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor
###end article-title 36
###begin article-title 37
###xml 61 66 <span type="species:ncbi:9606">human</span>
Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3
###end article-title 37
###begin article-title 38
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production
###end article-title 38
###begin article-title 39
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer
###end article-title 39
###begin article-title 40
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer
###end article-title 40
###begin article-title 41
VEGF gene polymorphisms and susceptibility to rheumatoid arthritis
###end article-title 41
###begin article-title 42
Vascular endothelial growth factor gene polymorphisms in Behcet's disease
###end article-title 42
###begin article-title 43
TNM staging for malignancies of the digestive tract: 2003 changes and beyond
###end article-title 43
###begin article-title 44
Denaturing high-performance liquid chromatography: a review
###end article-title 44
###begin article-title 45
DHPLC in clinical molecular diagnostic services
###end article-title 45
###begin article-title 46
A comparison of bayesian methods for haplotype reconstruction from population genotype data
###end article-title 46
###begin article-title 47
A common polymorphism in the 5' untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes
###end article-title 47
###begin article-title 48
Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study
###end article-title 48
###begin article-title 49
Influence of cytokine gene polymorphisms on the development of prostate cancer
###end article-title 49
###begin article-title 50
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk
###end article-title 50
###begin article-title 51
Vascular endothelial growth factor polymorphism in gastric cancer development, prognosis, and survival
###end article-title 51
###begin article-title 52
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer
###end article-title 52
###begin article-title 53
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes
###end article-title 53
###begin article-title 54
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
###end article-title 54
###begin article-title 55
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels
###end article-title 55
###begin article-title 56
###xml 38 43 <span type="species:ncbi:9606">human</span>
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter
###end article-title 56
###begin p 57
###xml 70 108 70 108 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kyungpook National University Hospital</funding-source>
This work was supported by a BioMedical Research Institute grant from Kyungpook National University Hospital (2006).
###end p 57
###begin p 58
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Algorithm for genotyping of VEGF gene polymorphisms using a polymerase chain reaction/denaturing high-performance liquid chromatography (PCR/DHPLC) assay.
###end p 58
###begin p 59
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients with colorectal cancer and controls
###end p 59
###begin p 60
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
*, tested in 462 patients. CEA, carcinoembryonic antigen.
###end p 60
###begin p 61
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Genotype distributions (%) and allele frequencies in patients with colorectal cancer and controls
###end p 61
###begin p 62
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 3 4 3 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 34 35 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
*, p value was estimated using chi2-test for distribution of three genotypes.
###end p 62
###begin p 63
CI, confidence interval.
###end p 63
###begin p 64
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Association of VEGF gene polymorphisms with clinical characteristics in patients with colorectal cancer (n=465)
###end p 64
###begin p 65
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
*, tested in 462 patients.
###end p 65
###begin p 66
VEGF, vascular endothelial growth factor; OR, odds ratio; CI, confidence interval; LN, lymph node; CEA, carcinoembryonic antigen.
###end p 66
###begin p 67
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Association of VEGF gene polymorphisms with pathologic characteristics in patients with colorectal cancer
###end p 67
###begin p 68
VEGF, vascular endothelial growth factor; OR, odds ratio; CI, confidence interval; LN, lymph node.
###end p 68
###begin p 69
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Distribution of VEGF haplotypes predicted by Bayesian algorithm in patients with colorectal cancer and controls
###end p 69
###begin p 70
VEGF, vascular endothelial growth factor; CI, confidence interval.
###end p 70

